| Renal Cell Carcinoma
Bavencio vs Torisel
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Bavencio vs Torisel with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTorisel has a higher rate of injection site reactions vs Bavencio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Torisel but not Bavencio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bavencio
Torisel
At A Glance
IV infusion
Every 2 weeks
PD-L1 blocking antibody
IV infusion
Once weekly
mTOR inhibitor
Indications
- Merkel cell carcinoma
- Urothelial Carcinoma
- Renal Cell Carcinoma
- Renal Cell Carcinoma
Dosing
Merkel cell carcinoma, Urothelial Carcinoma 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
Renal Cell Carcinoma 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks in combination with axitinib 5 mg orally twice daily (12 hours apart) with or without food until disease progression or unacceptable toxicity.
Renal Cell Carcinoma 25 mg administered as an IV infusion over 30-60 minutes once weekly; continue until disease progression or unacceptable toxicity.
Contraindications
—
- Bilirubin >1.5x ULN
Adverse Reactions
Most common (>=20%) fatigue, musculoskeletal pain, diarrhea, hypertension, nausea, rash, infusion-related reaction, cough, constipation, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased appetite, hypothyroidism, hepatotoxicity, dyspnea, abdominal pain, urinary tract infection, headache
Serious immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, myocarditis, neurological toxicities), infusion-related reactions, complications of allogeneic HSCT, major adverse cardiovascular events
Postmarketing neutropenia, sclerosing cholangitis
Most common (>=30%) Rash, asthenia, mucositis, nausea, edema, anorexia
Serious Hypersensitivity/infusion reactions, hepatic impairment, hyperglycemia/glucose intolerance, infections, interstitial lung disease, hyperlipidemia, bowel perforation, renal failure, wound healing complications, intracerebral hemorrhage
Postmarketing Angioedema, rhabdomyolysis, Stevens-Johnson Syndrome, complex regional pain syndrome, pancreatitis, cholecystitis, cholelithiasis
Pharmacology
Avelumab is a human IgG1 lambda monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors on T cells to restore anti-tumor immune responses; it also induces antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.
Temsirolimus is an mTOR inhibitor that binds to FKBP-12; the protein-drug complex inhibits mTOR activity, blocking phosphorylation of p70S6k and S6 ribosomal protein downstream in the PI3 kinase/AKT pathway, resulting in G1 growth arrest in tumor cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bavencio
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (0/12)
Torisel
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Bavencio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Torisel
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Bavencio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Torisel
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bavencio.
Cost estimate not availableAssistance Fund: Renal Cell Carcinoma (RCC): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BavencioView full Bavencio profile
ToriselView full Torisel profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.